WEBSITE BSE:0 NSE: Inc. Year: 1999 Industry: Hospital & Healthcare Services My Bucket: Add Stock
Last updated: 15:47
No Notes Added Yet
Vaidya Sane Ayurved Laboratories Ltd is a renowned company specializing in Ayurvedic healthcare products and remedies. With a rich legacy dating back several decades, the company has established itself as a trusted name in the field of Ayurveda. Vaidya Sane Ayurved Laboratories is committed to providing high-quality, natural, and authentic Ayurvedic formulations that promote holistic well-being. The company's product portfolio includes a wide range of herbal medicines, dietary supplements, skincare and haircare products, and wellness solutions...Read More
Vaidya Sane Ayurved Laboratories Ltd is a renowned company specializing in Ayurvedic healthcare products and remedies. With a rich legacy dating back several decades, the company has established itself as a trusted name in the field of Ayurveda. Vaidya Sane Ayurved Laboratories is committed to providing high-quality, natural, and authentic Ayurvedic formulations that promote holistic well-being. The company's product portfolio includes a wide range of herbal medicines, dietary supplements, skincare and haircare products, and wellness solutions. These products are formulated using traditional Ayurvedic principles and meticulously sourced ingredients to ensure their effectiveness and safety. Vaidya Sane Ayurved Laboratories prioritizes research and innovation, continuously striving to combine traditional wisdom with modern scientific advancements. The company follows strict quality control measures at every stage of production, adhering to international standards. With a customer-centric approach, Vaidya Sane Ayurved Laboratories aims to enhance the health and vitality of individuals worldwide through the power of Ayurveda. Their commitment to excellence, integrity, and sustainable practices has earned them a prominent position in the global Ayurvedic industry. ...Read Less
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹259 Cr.
Stock P/E 36.2
P/B 4.1
Current Price ₹246
Book Value ₹ 59.5
Face Value 10
52W High ₹335
Dividend Yield 0%
52W Low ₹ 128
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) |
|---|
| Net Sales |
| Other Income |
| Total Income |
| Total Expenditure |
| Operating Profit |
| Interest |
| Depreciation |
| Exceptional Income / Expenses |
| Profit Before Tax |
| Provision for Tax |
| Profit After Tax |
| Adjustments |
| Profit After Adjustments |
| Adjusted Earnings Per Share |
| #(Fig in Cr.) | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|
| Net Sales | 99 | 99 | 90 | |
| Other Income | 1 | 2 | 2 | |
| Total Income | 101 | 101 | 92 | |
| Total Expenditure | 91 | 95 | 76 | |
| Operating Profit | 10 | 6 | 15 | |
| Interest | 1 | 0 | 0 | |
| Depreciation | 3 | 3 | 4 | |
| Exceptional Income / Expenses | 0 | 0 | -1 | |
| Profit Before Tax | 6 | 3 | 10 | |
| Provision for Tax | 2 | 1 | 3 | |
| Profit After Tax | 5 | 2 | 7 | |
| Adjustments | 0 | -0 | -0 | |
| Profit After Adjustments | 5 | 2 | 7 | |
| Adjusted Earnings Per Share | 4.6 | 1.9 | 6.8 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | -9% | 0% | 0% | 0% |
| Operating Profit CAGR | 150% | 0% | 0% | 0% |
| PAT CAGR | 250% | 0% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 97% | 2% | NA% | NA% |
| ROE Average | 14% | 10% | 10% | 10% |
| ROCE Average | 17% | 14% | 14% | 14% |
| #(Fig in Cr.) | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Shareholder's Funds | 40 | 56 | 63 |
| Minority's Interest | 0 | 0 | 0 |
| Borrowings | 0 | 0 | 0 |
| Other Non-Current Liabilities | 1 | 2 | 3 |
| Total Current Liabilities | 13 | 12 | 11 |
| Total Liabilities | 55 | 70 | 77 |
| Fixed Assets | 21 | 28 | 34 |
| Other Non-Current Assets | 6 | 10 | 13 |
| Total Current Assets | 28 | 31 | 30 |
| Total Assets | 55 | 70 | 77 |
| #(Fig in Cr.) | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Opening Cash & Cash Equivalents | 3 | 2 | 2 |
| Cash Flow from Operating Activities | 0 | -1 | 11 |
| Cash Flow from Investing Activities | 1 | -13 | -10 |
| Cash Flow from Financing Activities | -1 | 15 | -1 |
| Net Cash Inflow / Outflow | -1 | 1 | -0 |
| Closing Cash & Cash Equivalent | 2 | 2 | 2 |
| # | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Earnings Per Share (Rs) | 4.6 | 1.88 | 6.78 |
| CEPS(Rs) | 7.07 | 4.88 | 10.75 |
| DPS(Rs) | 0.25 | 0 | 0 |
| Book NAV/Share(Rs) | 38.48 | 40.1 | 59.44 |
| Core EBITDA Margin(%) | 8.6 | 4.54 | 15.17 |
| EBIT Margin(%) | 7.35 | 3.14 | 11.27 |
| Pre Tax Margin(%) | 6.49 | 2.88 | 11.02 |
| PAT Margin (%) | 4.87 | 2 | 7.96 |
| Cash Profit Margin (%) | 7.49 | 5.17 | 12.59 |
| ROA(%) | 8.82 | 3.2 | 9.78 |
| ROE(%) | 11.95 | 4.82 | 13.66 |
| ROCE(%) | 17.96 | 6.37 | 16.7 |
| Receivable days | 22.05 | 22.12 | 27.6 |
| Inventory Days | 12.56 | 13.83 | 15.99 |
| Payable days | 118.46 | 114.04 | 152.09 |
| PER(x) | 51.12 | 92.39 | 13.81 |
| Price/Book(x) | 6.11 | 4.34 | 1.58 |
| Dividend Yield(%) | 0.11 | 0 | 0 |
| EV/Net Sales(x) | 2.47 | 1.84 | 1.09 |
| EV/Core EBITDA(x) | 24.82 | 29.11 | 6.31 |
| Net Sales Growth(%) | 0 | 0.16 | -9.55 |
| EBIT Growth(%) | 0 | -57.21 | 224.59 |
| PAT Growth(%) | 0 | -58.81 | 259.44 |
| EPS Growth(%) | 0 | -59.03 | 260.17 |
| Debt/Equity(x) | 0 | 0.04 | 0.02 |
| Current Ratio(x) | 2.16 | 2.7 | 2.7 |
| Quick Ratio(x) | 1.89 | 2.34 | 2.36 |
| Interest Cover(x) | 8.5 | 12.25 | 44.76 |
| Total Debt/Mcap(x) | 0 | 0.01 | 0.01 |
| # | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 66.34 | 66.34 | 66.34 | 66.34 | 66.34 | 66.34 | 66.34 | 66.34 | 66.34 | 66.34 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.21 | 0 | 0 |
| Public | 33.66 | 33.66 | 33.66 | 33.66 | 33.66 | 33.66 | 33.66 | 33.45 | 33.66 | 33.66 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 0.35 | 0.35 | 0.35 | 0.35 | 0.35 | 0.35 | 0.35 | 0.35 | 0.35 | 0.35 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1.05 | 1.05 | 1.05 | 1.05 | 1.05 | 1.05 | 1.05 | 1.05 | 1.05 | 1.05 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
ChatGPT
Claude
Perplexity
